← Leaderboards
Adam Scott Duerfeldt
University Of Oklahoma
$4,414,399
Attributed
$6,247,610
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,247,610 · 5
By mechanism
R01$4,566,911 · 2
P20$841,331 · 1
R21$839,368 · 2
Top collaborators
- Valentin V Rybenkov2 shared
- Derek S Tan2 shared
- Helen I. Zgurskaya2 shared
Others in their field
Other Emerging Leaders on “Public Health”
- Kimberly Smith · Ppd Development Lp$115,671,664
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Mark Marino · Venturewell$51,488,542
- Susan M Landau · University Of California Berkeley$47,252,026
- Leonard Freedman · Leidos Biomedical Research, Inc.$39,554,144
Research focus
Public HealthCellsUnited StatesComplexNovel TherapeuticsPharmaceutical PreparationsDesignSmall MoleculeExhibitsSuccessStructureProtein IsoformsProductionDiabetes MellitusAnalogLeadLeukostasisModalityApoptosisInflammatoryAttenuatedAgonistBlindnessBlood Vessels
Grant awards (16)
Small-Molecule Penetration and Efflux in Gram-Negative Bacteria$1,203,141
R01 · FY2025 · AI
Bifunctional Inhibitors of STING as Chemical Probes for Diabetic Retinopathy$189,509
R21 · FY2025 · EY · contact PI
Small-Molecule Penetration and Efflux in Gram-Negative Bacteria$1,241,141
R01 · FY2024 · AI
Small Molecule PPAR-alpha Agonism as a Novel Approach to Treat Eye Vascular Diseases$388,677
R01 · FY2024 · EY · contact PI
Bifunctional Inhibitors of STING as Chemical Probes for Diabetic Retinopathy$228,009
R21 · FY2024 · EY · contact PI
Small Molecule PPAR-alpha Agonism as a Novel Approach to Treat Eye Vascular Diseases$388,677
R01 · FY2023 · EY · contact PI
Small Molecule PPAR-alpha Agonism as a Novel Approach to Treat Eye Vascular Diseases$435,436
R01 · FY2022 · EY · contact PI
Small Molecule PPAR-alpha Agonism as a Novel Approach to Treat Eye Vascular Diseases$451,838
R01 · FY2021 · EY · contact PI
Small Molecule PPAR-alpha Agonism as a Novel Approach to Treat Eye Vascular Diseases$288,515
R01 · FY2020 · EY · contact PI
Structure, Function, and Therapeutic Potential of Clostridium difficile Caseinolytic Protease P (Duerfeldt)$210,167
P20 · FY2020 · GM · contact PI
Small Molecule PPAR-alpha Agonism as a Novel Approach to Treat Eye Vascular Diseases$169,486
R01 · FY2020 · EY · contact PI
Structure, Function, and Therapeutic Potential of Clostridium difficile Caseinolytic Protease P (Duerfeldt)$210,167
P20 · FY2019 · GM · contact PI
Structure, Function, and Therapeutic Potential of Clostridium difficile Caseinolytic Protease P (Duerfeldt)$210,167
P20 · FY2018 · GM · contact PI
Hit to Lead Optimization of a Systemically Available Treatment for Diabetic Retinopathy$191,550
R21 · FY2018 · EY · contact PI
Hit to Lead Optimization of a Systemically Available Treatment for Diabetic Retinopathy$230,300
R21 · FY2017 · EY · contact PI
Structure, Function, and Therapeutic Potential of Clostridium difficile Caseinolytic Protease P (Duerfeldt)$210,830
P20 · FY2017 · GM · contact PI